ArticleOncology research2026
Integrative Machine Learning and Experimental Validation Identify MYBL2 as a Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) presents with poor treatment outcomes, creating an urgent need for novel biomarkers to improve diagnosis, prognosis, and precision medicine. While the MYB family of oncogenes is implicated in cancer, the role and regulatory mechanisms of its member, particularly MYB proto-oncogene like 2 (MYBL2), remain underexplored in HCC. Therefore, this study aimed to systematically validate the clinical significance of MYBL2, elucidate its functional role in tumor progression and drug sensitivity, and identify its upstream regulatory mechanisms using an integrative machine learning and experimental framework. Methods: We applied an integrative pipeline combining LASSO-based feature selection on TCGA and GEO cohorts, single-cell transcriptomics, pharmacogenomic surveys, and CRISPR dependency screens. These computational approaches were complemented by Results: MYBL2 robustly discriminated tumor from normal liver (AUC = 0.968), and high expression was associated with adverse features, including higher grade, microvascular invasion, HBV positivity, nonresponse to TACE, and worse survival. A nomogram combining MYBL2 with AJCC stage improved 1-, 3-, and 5-year AUCs versus stage alone. MYBL2 correlated with proliferative biomarkers (AFP, MKI67, PCNA, BIRC5) and CRISPR knockout inhibited growth in most HCC lines. High MYBL2 expression was associated with greater sensitivity to sorafenib in pharmacogenomic screens and was linked to an immunosuppressive microenvironment and higher MSI. Mechanistically, miR-29a was shown to suppress MYBL2 translation by directly binding to its 3 Conclusions: MYBL2 is a potent diagnostic and prognostic biomarker in HCC that also predicts sorafenib sensitivity. Our findings establish a clear regulatory link where MYBL2 is a direct and functionally important target of the tumor-suppressive miR-29a. This positions MYBL2 as a tractable target for miR-29a-based therapeutic strategies, warranting clinical validation for patient stratification and treatment development in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.